209 related articles for article (PubMed ID: 36005485)
1. Heteronemin and Tetrac Induce Anti-Proliferation by Blocking EGFR-Mediated Signaling in Colorectal Cancer Cells.
Unson S; Chang TC; Yang YN; Wang SH; Huang CH; Crawford DR; Huang HM; Li ZL; Lin HY; Whang-Peng J; Wang K; Davis PJ; Li WS
Mar Drugs; 2022 Jul; 20(8):. PubMed ID: 36005485
[TBL] [Abstract][Full Text] [Related]
2. Combined Treatment of Heteronemin and Tetrac Induces Antiproliferation in Oral Cancer Cells.
Huang CH; Huang TY; Chang WJ; Pan YS; Chu HR; Li ZL; Unson S; Chin YT; Lin CY; Huang HM; Hsiung CN; Gionfra F; De Vito P; Pedersen JZ; Incerpi S; Chen YR; Lee SY; Lin HY; Davis PJ; Whang-Peng J; Wang K
Mar Drugs; 2020 Jul; 18(7):. PubMed ID: 32630719
[TBL] [Abstract][Full Text] [Related]
3. Heteronemin and tetrac derivatives suppress non-small cell lung cancer growth via ERK1/2 inhibition.
Chung CC; Huang TY; Chu HR; De Luca R; Candelotti E; Huang CH; Yang YSH; Incerpi S; Pedersen JZ; Lin CY; Huang HM; Lee SY; Li ZL; ChangOu CA; Li WS; Davis PJ; Lin HY; Whang-Peng J; Wang K
Food Chem Toxicol; 2022 Mar; 161():112850. PubMed ID: 35151786
[TBL] [Abstract][Full Text] [Related]
4. NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer.
Huang TY; Chang TC; Chin YT; Pan YS; Chang WJ; Liu FC; Hastuti ED; Chiu SJ; Wang SH; Changou CA; Li ZL; Chen YR; Chu HR; Shih YJ; Cheng RH; Wu A; Lin HY; Wang K; Whang-Peng J; Mousa SA; Davis PJ
Cells; 2020 Aug; 9(8):. PubMed ID: 32756527
[TBL] [Abstract][Full Text] [Related]
5. The power of heteronemin in cancers.
Wang K; Chen YF; Yang YSH; Huang HM; Lee SY; Shih YJ; Li ZL; Whang-Peng J; Lin HY; Davis PJ
J Biomed Sci; 2022 Jun; 29(1):41. PubMed ID: 35705962
[TBL] [Abstract][Full Text] [Related]
6. The combination of tetraiodothyroacetic acid and cetuximab inhibits cell proliferation in colorectal cancers with different K-ras status.
Lee YS; Chin YT; Yang YSH; Wei PL; Wu HC; Shih A; Lu YT; Pedersen JZ; Incerpi S; Liu LF; Lin HY; Davis PJ
Steroids; 2016 Jul; 111():63-70. PubMed ID: 26980146
[TBL] [Abstract][Full Text] [Related]
7. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
8. AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer.
Ye H; Liu Y; Wu K; Luo H; Cui L
Cell Commun Signal; 2020 Jul; 18(1):115. PubMed ID: 32703218
[TBL] [Abstract][Full Text] [Related]
9. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
[No Abstract] [Full Text] [Related]
10. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
[TBL] [Abstract][Full Text] [Related]
11. Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS
Feng J; Hu Z; Xia X; Liu X; Lian Z; Wang H; Wang L; Wang C; Zhang X; Pang X
Oncogene; 2023 May; 42(20):1620-1633. PubMed ID: 37020035
[TBL] [Abstract][Full Text] [Related]
12. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279
[TBL] [Abstract][Full Text] [Related]
13. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [
